BIOLASE, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Debt - Additional Information (Detail)

Debt - Additional Information (Detail)												1 Months Ended						3 Months Ended			9 Months Ended		12 Months Ended
Debt - Additional Information (Detail)	Aug. 12, 2020 USD ($)	Jul. 23, 2020 USD ($) shares	Jul. 22, 2020 USD ($) $ / shares shares	Jun. 10, 2020 USD ($)	Jun. 08, 2020 USD ($)	May 22, 2020 USD ($)	Apr. 13, 2020 USD ($)	Oct. 28, 2019 USD ($)	May 07, 2019 USD ($)	Nov. 09, 2018 USD ($) Day $ / shares shares	Sep. 27, 2018 USD ($) $ / shares	Sep. 30, 2020 USD ($) $ / shares shares	Aug. 31, 2020 $ / shares	Jul. 31, 2020 USD ($)	Mar. 31, 2020 USD ($) $ / shares shares	Nov. 30, 2019 $ / shares	Oct. 31, 2019 $ / shares	Sep. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2019 USD ($)	Jun. 30, 2020 USD ($)	May 15, 2020 USD ($)	Apr. 30, 2020 USD ($)	Apr. 14, 2020 USD ($)	Dec. 31, 2019 USD ($) $ / shares shares	May 31, 2019 $ / shares	Mar. 31, 2019 USD ($)	Mar. 06, 2018 USD ($) $ / shares
Debt Instrument [Line Items]
Proceeds from offering, net of underwriting discounts and commissions			$ 16,100,000											$ 8,000,000
Company maintains unrestricted cash														$ 1,500,000
Proceeds from offering				$ 6,900,000
Borrowings on credit facility																					$ 3,000,000
Common stock value												$ 93,000						$ 93,000			93,000						$ 31,000
EBITDA target																		$ (3,667,000)		$ (4,882,000)	$ (12,997,000)	$ (12,573,000)
Series F Preferred stock, shares issued \| shares												1,000						1,000			1,000						0
Series F Preferred stock, par value \| $ / shares												$ 0.001						$ 0.001			$ 0.001						$ 0.001
Warrants issued to purchase shares of common stock \| shares			45,000,000
Proceeds from the exercise of common stock warrants																					$ 46,000
Non current term loans												$ 3,140,000						$ 3,140,000			3,140,000
Warrants adjusted exercise price \| $ / shares																			$ 0.60
Warrants, estimated fair value																					(5,850,000)
Change in fair value of warrants																					(5,850,000)
Series F Convertible Preferred Stock
Debt Instrument [Line Items]
Proceeds from offering, net of underwriting discounts and commissions																					18,000,000
Common stock value												$ 1,000						$ 1,000			$ 1,000
Series F Preferred stock, shares issued \| shares		18,000
SWK Warrants
Debt Instrument [Line Items]
Warrants adjusted strike price \| $ / shares															$ 0.49	$ 1.00	$ 1.00
Warrants issued to purchase shares of common stock \| shares										372,023					487,198
Exercise price of warrants \| $ / shares										$ 1.34					$ 0.39198
Warrants expire date										Nov. 09, 2026
Number of trading days of average closing price of common stock \| Day										10
Warrants expiration period										8 years
Warrants fair value assumptions, expected volatility rate										81.79%
Warrants fair value assumptions annual dividend per share \| $ / shares										$ 0.00
Warrants fair value assumptions, risk-free interest rate										3.13%
Warrants, estimated fair value										$ 400,000					$ 100,000
Additional Warrants issued to purchase shares of common stock \| shares															63,779
Change in fair value of warrants										400,000					$ 100,000
DPG Warrants
Debt Instrument [Line Items]
Finder's fee										$ 400,000
Warrants issued to purchase shares of common stock \| shares										279,851
Exercise price of warrants \| $ / shares										$ 1.34
Warrants expire date										Nov. 09, 2026
Number of trading days of average closing price of common stock \| Day										10
Warrants expiration period										8 years
Warrants fair value assumptions, expected volatility rate										81.79%
Warrants fair value assumptions annual dividend per share \| $ / shares										$ 0.00
Warrants fair value assumptions, risk-free interest rate										3.13%
Warrants, estimated fair value										$ 300,000
Change in fair value of warrants										$ 300,000
Adjusted exercise price of warrants \| $ / shares												$ 0.62	$ 0.38
DPG Warrants \| Warrants Issued on November 9, 2018
Debt Instrument [Line Items]
Exercise price of warrants \| $ / shares										$ 1.34		0.8767						$ 0.8767			$ 0.8767
DPG Warrants \| Warrants Issued on May, 2019
Debt Instrument [Line Items]
Exercise price of warrants \| $ / shares												$ 1.4197						$ 1.4197			$ 1.4197							$ 2.17
Original Western Alliance Warrant
Debt Instrument [Line Items]
Exercise price of warrants \| $ / shares																														$ 2.35
Western Alliance Warrant
Debt Instrument [Line Items]
Exercise price of warrants \| $ / shares											$ 2.13
Warrants expire date											Sep. 27, 2028
SWK Warrants and DPG Warrants
Debt Instrument [Line Items]
Warrants effective-interest method amortization period																					5 years
Credit Agreement, First Amendment \| SWK Warrants
Debt Instrument [Line Items]
Additional warrants to purchase common stock value									$ 200,000
Credit Agreement, First Amendment \| DPG Warrants
Debt Instrument [Line Items]
Additional warrants to purchase common stock value									100,000
Additional finders fee									100,000
Paycheck Protection Program
Debt Instrument [Line Items]
Loan granted amount from bank																										$ 2,980,000
Note issued date							Apr. 13, 2020
Note maturity date							Apr. 13, 2022
Note interest rate per annum							1.00%
Note payable commencing date							Nov. 01, 2020
Note prepayment penalties							$ 0
Non current term loans												$ 3,000,000						$ 3,000,000			$ 3,000,000
EIDL Loan
Debt Instrument [Line Items]
Note interest rate per annum						3.75%
Loan principal amount						$ 150,000
Loan periodic payment						$ 731
Loan periodic payment terms						installment payments, including principal and interest, are due monthly beginning twelve months from the date of the EIDL Loan
Loan balance payment terms						The balance of principal and interest is payable thirty years from the date of the promissory note.
Maximum \| Original Western Alliance Warrant
Debt Instrument [Line Items]
Warrants issued to purchase shares of common stock equal value																														$ 120,000
Maximum \| Western Alliance Warrant
Debt Instrument [Line Items]
Warrants issued to purchase shares of common stock equal value											$ 120,000
Minimum [Member]
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets																			$ 3,000,000				$ 3,000,000
Pacific Mercantile Bank
Debt Instrument [Line Items]
Proceeds from offering		$ 16,000,000
Pacific Mercantile Bank \| Paycheck Protection Program
Debt Instrument [Line Items]
Original payment deferment period														6 months
Loan forgiveness description of period														Company’s loan forgiveness to PMB or if no forgiveness is requested to ten months after the end of the 24-week measurement period
Pacific Mercantile Bank \| Maximum \| Paycheck Protection Program
Debt Instrument [Line Items]
Non-payroll costs percentage rate for loan forgivness increases														40.00%
Pacific Mercantile Bank \| Minimum [Member] \| Paycheck Protection Program
Debt Instrument [Line Items]
Non-payroll costs percentage rate for loan forgivness increases														25.00%
SWK Loan
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity																													$ 12,500,000
Repayments of loan										$ 700,000
Line of credit facility term										5 years
Borrowings on credit facility										$ 12,500,000
Debt instrument, repayment of interest-only on loan period										2 years
Debt instrument, principal repayments beginning term										2021
Debt instrument, maturity term										2023
Debt instrument covenant description																					(i) maintain unencumbered liquid assets of (A) no less than $1.5 million or (B) the sum of aggregate cash flow from operations less capital expenditures, (ii) achieve certain revenue and EBITDA levels during the first two years of the loan, (iii) limit future borrowing, investments and dividends, and (iv) submit monthly and quarterly financial reporting.
Debt issuance costs										$ 1,000,000
Loan origination fee										200,000
Finder's fee										400,000
Legal and other fees										$ 400,000
Interest expense																		$ 600,000		600,000	$ 1,800,000	1,600,000
Weighted-average interest rate												12.25%						12.25%			12.25%
SWK Loan \| LIBOR
Debt Instrument [Line Items]
Line of credit facility interest rate description																					London Interbank Bank Offered Rate (“LIBOR”) plus 10% or another index that approximates LIBOR as close as possible if and when LIBOR no longer exists.
Line of credit facility bearing floating interest rate per annum										10.00%
SWK Loan \| Credit Agreement, First Amendment
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity									15,000,000
Debt instrument covenant description																					(a) adjust minimum revenue and EBITDA levels, (b) require the Company to have a shelf registration statement declared effective by the Securities and Exchange Commission before September 30, 2019, with a proposed maximum aggregate offering price of at least $10.0 million if the Company did not reach set minimum revenue levels for the three-month period ended September 30, 2019, and (c) require minimum liquidity of $1.5 million at all times. The First Amendment provided that if aggregate minimum revenue and EBITDA levels were not achieved by September 30, 2019, the minimum liquidity requirement would be increased to $3.0 million, until the Company has obtained additional equity or debt funding of no less than $5.0 million.
Minimum level of liquidity financial covenant									1,500,000
Additional equity or debt funding requirement until minimum liquidity is met									5,000,000																		$ 5,000,000
Maximum aggregate offering price									10,000,000
Increase in minimum liquidity requirement if aggregate minimum revenue and EBITDA levels are not achieved									3,000,000
Financial covenant additional borrowings																											2,500,000
Loan origination and other fees to be paid									$ 100,000
SWK Loan \| Credit Agreement, Second Amendment [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity																				$ 5,000,000		5,000,000
SWK Loan \| Credit Agreement, Fifth Amendment
Debt Instrument [Line Items]
Proceeds from offering					$ 6,900,000
Warrants issued to purchase shares of common stock \| shares			2,500
Exercise price of warrants \| $ / shares			$ 0.40
Proceeds from the exercise of common stock warrants			$ 18,000,000
SWK Loan \| Credit Agreement, Fifth Amendment \| Series F Convertible Preferred Stock
Debt Instrument [Line Items]
Series F Preferred stock, shares issued \| shares			18,000
Series F Preferred stock, par value \| $ / shares			$ 0.001
SWK Loan \| Credit Agreement, Sixth Amendment [Member]
Debt Instrument [Line Items]
Repayments of loan	$ 700,000
Incremental amendment fee	$ 25,000
SWK Loan \| Maximum
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets										$ 1,500,000
SWK Loan \| Maximum \| Credit Agreement, Fifth Amendment
Debt Instrument [Line Items]
Subordinated debt issued					$ 10,000,000														$ 10,000,000				10,000,000
SWK Loan \| Minimum [Member] \| Credit Agreement, Second Amendment [Member]
Debt Instrument [Line Items]
Gross proceeds from subordinated debt threshold limit																						$ 5,000,000
SWK Loan \| Minimum [Member] \| Credit Agreement, Fifth Amendment
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets																								$ 1,500,000
Revenue target																							41,000,000
EBITDA target																							$ 7,000,000
Western Alliance \| Business Financing Agreement
Debt Instrument [Line Items]
Repayments of loan										$ 900,000
Loan Agreement \| Pacific Mercantile Bank
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity								$ 3,000,000
Maximum borrowing base percentage of eligible accounts								90.00%
Maximum borrowing base percentage of eligible inventory								75.00%
Line of credit facility expiration date								Oct. 28, 2021
Interest rate								1.50%
Line of credit, outstanding borrowings												$ 0						$ 0			$ 0						0
Line of credit facility, unused availability												$ 1,500,000						1,500,000			$ 1,500,000						$ 2,700,000
Loan Agreement \| Pacific Mercantile Bank \| Maximum
Debt Instrument [Line Items]
Interest rate								6.00%
Loan Agreement \| Exim Bank
Debt Instrument [Line Items]
Line of credit facility expiration date								Oct. 28, 2020
Annual fee								$ 52,500
Termination fee								$ 30,000
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility description																					In April, 2020, the Company drew $3.0 million under the PMB Loan and repaid the balance in full during the second quarter. Interest incurred on the loan was not material. In May 2020 it was determined that the Company was not in compliance with the minimum unrestricted cash requirement under the PMB Loan’s existing covenants as of March 31, 2020. On July 30, 2020, the Company obtained a waiver for the covenant violation and entered into the First Amendment to the Loan and Security Agreement (the “First Amendment”)
Line of credit, outstanding borrowings																									$ 3,000,000
Repayments of loan																		$ 3,000,000